盐酸帕洛诺司琼

Palonosetron hydrochloride

	产品编号	CFN90009
	CAS编号	135729-62-3
	分子式 = 分子量	C₁₉H₂₅ClN₂O = 332.87
	产品纯度	>=98%
	物理属性	Powder
	化合物类型	Alkaloids
	植物来源	From Streptomycetaceae
ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用

提供自定义包装

产品名称	产品编号	CAS编号	包装	QQ客服
盐酸帕洛诺司琼	CFN90009	135729-62-3	10mg	QQ客服：3257982914
盐酸帕洛诺司琼	CFN90009	135729-62-3	20mg	QQ客服：3257982914
盐酸帕洛诺司琼	CFN90009	135729-62-3	50mg	QQ客服：3257982914
盐酸帕洛诺司琼	CFN90009	135729-62-3	100mg	QQ客服：3257982914

存储与注意事项

1. 在您收到产品后请检查产品。如无问题，请将产品存入冰霜并且样品瓶保持密封，产品可以存放长达24个月（2-8摄氏度）。

2. 只要有可能，产品溶解后，您应该在同一天应用于您的实验。但是，如果您需要提前做预实验，或者需要全部溶解，我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。通常，这些可用于长达两周。使用前，打开样品瓶前，我们建议您将产品平衡至室温至少1小时。

3. 需要更多关于溶解度，使用和处理的建议？请发送电子邮件至：service@chemfaces.com

订购流程

1. 在线订购

请联系我们QQ客服

2. 电话订购

请拨打电话：
027-84237683 或 027-84237783

3. 邮件或传真订购

发送电子邮件到: manager@chemfaces.com 或
发送传真到：027-84254680

提供订购信息

为了方便客户的订购，请需要订购ChemFaces产品的客户，在下单的时候请提供下列信息，以供我们快速为您建立发货信息。

1. 产品编号（CAS No.或产品名称）

2. 发货地址

3. 联系方法 (联系人，电话）

4. 开票抬头 (如果需要发票的客户）

5. 发票地址（发货地址与发票地址不同）

发货时间

1. 付款方式为100%预付款客户，我们将在确认收到货款后当天或1-3个工作日发货。

2. 付款方式为月结的客户，我们承诺在收到订单后当天或1-3个工作日内发货。

3. 如果客户所需要的产品，需要重新生产，我们有权告知客户，交货时间需要延期。

Description:

Palonosetron hydrochloride is the only serotonin receptor antagonist approved for prevention of delayed chemotherapy-induced nausea and vomiting (CINV) caused by moderate emetogenic chemotherapy (MEC).

Targets:

5-HT Receptor

In vitro:

Expert Opin Pharmacother. 2013 Apr;14(5):629-41.

An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.[Pubmed: 23414148]

Nausea and vomiting are well recognized in different clinical situations, suggesting that no single mechanism is likely to be responsible for their production.
METHODS AND RESULTS:
Chemotherapy-induced nausea and vomiting (CINV) can have a negative impact on quality of life and this may lead to a refusal of curative therapy or to a decline in palliative benefits offered by cytotoxic treatment. Palonosetron hydrochloride is a new agent in the class of 5-HT3 receptor antagonists (5-HT3RAs), and differs from the other agents by its higher receptor-binding affinity and longer half-life. These pharmacological properties have resulted in improved antiemetic activity in clinical trials, particularly in the treatment of delayed CINV following moderate emetogenic chemotherapy (MEC). A systematic review of the medical literature was completed to inform this update. MEDLINE, the Cochrane Collaboration Library and meeting materials from ASCO and MASCC were all searched.
CONCLUSIONS:
Palonosetron hydrochloride was the only serotonin receptor antagonist approved for prevention of delayed CINV caused by MEC and its use was incorporated in guideline recommendations. To date, several treatment settings such as multiple day chemotherapy require further studies to improve emesis related to therapy.

In vivo:

Exp Ther Med. 2013 May;5(5):1418-1426.

The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting.[Pubmed: 23737892]

The current study aimed to evaluate the efficacy and safety of Palonosetron hydrochloride injection for preventing chemotherapy-induced moderate and severe nausea and vomiting.
METHODS AND RESULTS:
A multi-centered, randomly stratified, double-blind, double-dummy, parallel-group and positive-controlled trial was performed. A total of 240 patients who underwent chemotherapy treatment which induced moderate or severe vomiting were divided into the experimental and control groups. Half an hour before chemotherapy, the experimental group received a 0.25-mg Palonosetron hydrochloride injection, whereas the control group received a 3-mg granisetron injection. The acute vomiting complete remission rate (CRR) of the experimental group was not significantly different compared with that of the control group (P=0.35). The delayed vomiting CRR of the experimental group was significantly higher compared with that of the control group (P=0.002). No difference in full course vomiting CRR, vomiting control time, treatment failure time or acute nausea CRR was identified between the two groups. No significant differences in adverse events were observed between the experimental group and the control group. No significant differences in adverse reactions occurred between the experimental group and the control group (12.50%).
CONCLUSIONS:
Palonosetron hydrochloride injection had a better effect on delayed vomiting CRR than granisetron hydrochloride injection. The two injections exhibited similar effects on acute vomiting CRR, full course vomiting CRR, vomiting control time, treatment failure time (days), acute nausea CRR and adverse events.

产品名称	产品编号	CAS编号	分子式 = 分子量	位单	联系QQ
2-环己基乙胺; 2-Cyclohexylethylamine	CFN00069	4442-85-7	C₈H₁₇N = 127.23	5mg	QQ客服：1413575084
N-甲基环己烷乙胺; N-Methylcyclohexaneethaneamine	CFN00070	62141-38-2	C₉H₁₉N = 141.29	5mg	QQ客服：1413575084
3,3'-[Iminobis(methylene)]bis-2(3H)furanone; 3,3'-[Iminobis(methylene)]bis-2(3H)furanone	CFN00082	96562-86-6	C₁₀H₁₅NO₄ = 213.23	5mg	QQ客服：215959384
Cassipourine; Cassipourine	CFN00442	14051-10-6	C₁₄H₂₂N₂S₄ = 346.60	5mg	QQ客服：1413575084
酒石酸伐仑克林; Varenicline tartrate	CFN90008	375815-87-5	C₁₃H₁₃N₃.C₄H₆O₆ = 361.35	5mg	QQ客服：1413575084
盐酸帕洛诺司琼; Palonosetron hydrochloride	CFN90009	135729-62-3	C₁₉H₂₅ClN₂O = 332.87	20mg	QQ客服：2056216494
盐酸普拉克索; Pramipexole dihydrochloride	CFN90019	104632-25-9	C₁₀H₁₉Cl₂N₃S = 284.25	5mg	QQ客服：1457312923
雷美替胺; Ramelteon	CFN90021	166597-26-9	C₁₃H₂₁NO₂ = 259.34	5mg	QQ客服：2159513211
凝血酸，氨甲环酸; Tranexamic acid	CFN90569	1197-18-8	C₈H₁₅NO₂ = 157.21	20mg	QQ客服：215959384

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	3.0042 mL	15.0209 mL	30.0418 mL	60.0835 mL	75.1044 mL
5 mM	0.6008 mL	3.0042 mL	6.0084 mL	12.0167 mL	15.0209 mL
10 mM	0.3004 mL	1.5021 mL	3.0042 mL	6.0084 mL	7.5104 mL
50 mM	0.0601 mL	0.3004 mL	0.6008 mL	1.2017 mL	1.5021 mL
100 mM	0.03 mL	0.1502 mL	0.3004 mL	0.6008 mL	0.751 mL

盐酸帕洛诺司琼

Palonosetron hydrochloride

信息支持

联系方式